Suven Life gets 2 product patents in Canada, Hong Kong

Patents related to treatment of neurodegenerative diseases

Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has received a product patent each from Hong Kong and Canada. These patents correspond to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and are valid through 2023 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. These are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's, attention deficient hyperactivity disorder, Huntington's, Parkinson and Schizophrenia.

With these new patents, Suven now has 15 granted patents from Canada and 14 product patents from Hong Kong. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II, Suven said in a filing to the BSE on Thursday.

Suven Life's scrip is currently trading at Rs 78.30 on the BSE, up 3.92%, over the previous close of Rs 75.35 a share.